The National Institutes of Health last month awarded one-year grants to Calando Pharmaceuticals and SomaGenics to support development of improved delivery methods for RNAi molecules.
Calando Pharmaceuticals' grant, issued by the NIH's National Institute of General Medical Sciences, is worth $100,000 and will fund research into a novel, systemic delivery system for modified siRNA duplexes.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
